Elicera Therapeutics
Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform
The Communication means that the European Patent Office intends to grant the European patent application after the completion of certain formal steps. Once granted, the patent can be kept in force until 2036.
"We are very pleased to receive a Notice of Allowance in Europe for this important patent application as it adds significant value to our patent portfolio and strengthens the protection around one of our key assets, says Jamal El-Mosleh, CEO of Elicera Therapeutics.
| Datum | 2023-07-11, kl 08:57 |
| Källa | Cision |
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.